CVS Health Co. (NYSE:CVS) Shares Sold by Impax Asset Management Group plc

Impax Asset Management Group plc lessened its holdings in CVS Health Co. (NYSE:CVS) by 4.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 440,979 shares of the pharmacy operator’s stock after selling 19,049 shares during the quarter. Impax Asset Management Group plc’s holdings in CVS Health were worth $19,796,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Crestwood Advisors Group LLC grew its position in CVS Health by 2.2% during the 4th quarter. Crestwood Advisors Group LLC now owns 19,380 shares of the pharmacy operator’s stock worth $870,000 after purchasing an additional 408 shares during the last quarter. IFP Advisors Inc lifted its position in CVS Health by 91.3% during the 4th quarter. IFP Advisors Inc now owns 21,413 shares of the pharmacy operator’s stock worth $961,000 after acquiring an additional 10,222 shares during the period. B&D White Capital Company LLC purchased a new stake in CVS Health during the 4th quarter valued at about $417,000. Howard Capital Management Inc. increased its holdings in shares of CVS Health by 13.6% in the fourth quarter. Howard Capital Management Inc. now owns 13,846 shares of the pharmacy operator’s stock valued at $622,000 after purchasing an additional 1,653 shares during the period. Finally, Wealthspire Advisors LLC raised its stake in shares of CVS Health by 10.1% in the fourth quarter. Wealthspire Advisors LLC now owns 15,962 shares of the pharmacy operator’s stock worth $717,000 after purchasing an additional 1,468 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Stock Down 0.8 %

Shares of NYSE CVS opened at $62.95 on Tuesday. The firm has a market cap of $79.37 billion, a price-to-earnings ratio of 17.20, a price-to-earnings-growth ratio of 0.98 and a beta of 0.61. The company’s 50-day simple moving average is $52.72 and its 200-day simple moving average is $56.25. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $80.75.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Equities analysts predict that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were issued a $0.665 dividend. The ex-dividend date was Thursday, January 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 4.23%. CVS Health’s payout ratio is currently 72.68%.

Insiders Place Their Bets

In other CVS Health news, Director Michael F. Mahoney purchased 30,000 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were purchased at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the purchase, the director now owns 39,356 shares in the company, valued at approximately $2,625,045.20. This represents a 320.65 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 0.24% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

CVS has been the topic of several research reports. Piper Sandler cut their price target on shares of CVS Health from $72.00 to $64.00 and set an “overweight” rating on the stock in a report on Monday, November 25th. Royal Bank of Canada reduced their target price on shares of CVS Health from $68.00 to $58.00 and set an “outperform” rating for the company in a report on Friday, November 15th. Wells Fargo & Company upped their price target on shares of CVS Health from $68.00 to $73.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Barclays lifted their price objective on CVS Health from $71.00 to $73.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Finally, Edward Jones upgraded CVS Health from a “hold” rating to a “buy” rating in a research note on Thursday, January 30th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $70.00.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.